Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Calithera Biosciences, Inc. (CALA)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
0.1971+0.0012 (+0.61%)
At close: 04:00PM EDT
0.1954 -0.00 (-0.86%)
After hours: 07:32PM EDT
Advertisement

Calithera Biosciences, Inc.

343 Oyster Point Boulevard
Suite 200
South San Francisco, CA 94080
United States
650 870 1000
https://www.calithera.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees63

Key Executives

NameTitlePayExercisedYear Born
Dr. Susan M. Molineaux Ph.D.Founder, CEO, Pres & Director923.21kN/A1954
Ms. Stephanie WongCFO & Sec.616.4kN/A1974
Dr. Eric B. SjogrenSr. VP of Drug Discovery579.13kN/A1957
Dr. Christopher J. Molineaux Ph.D.Sr. VP of Devel.N/AN/A1953
Mr. Frank Parlati Ph.D.Sr. VP of ResearchN/AN/A1969
Dr. Emil T. Kuriakose M.D.Chief Medical OfficerN/AN/A1980
Dr. Susan B. Demo Ph.D.Sr. VP of R&D OperationsN/AN/AN/A
Dr. Allison Dillon Ph.D.Sr. VP of Commercial & Portfolio StrategyN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Calithera Biosciences, Inc., a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule compounds for tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. The company offers INCB001158, an orally bioavailable arginase inhibitor of arginase that is in Phase 1/2 clinical trial for the treatment of hematology and oncology. It is developing CB-280, an oral arginase inhibitor that has completed Phase 1b clinical trial for the treatment of cystic fibrosis and chronic airway infection; and ATG-037, an orally-bioavailable small molecule inhibitor of CD73, as well as CB-668, an orally administered inhibitor of the enzyme IL4I1. The company has a license agreement with Mars, Inc. to develop and commercialize Symbioscience's portfolio of arginase inhibitors for use in human healthcare. It also has clinical trial collaboration with Pfizer to evaluate Pfizer's PARP inhibitor talazoparib and CDK4/6 inhibitor palbociclib, each in combination with telaglenasta. In addition, the company has a collaboration and license agreement with Incyte Corporation for the research, development, and commercialization of INCB001158, a small molecule arginase inhibitor for the treatment of hematology and oncology; and a license agreement with Antengene Corporation Ltd. for the development and commercialization of CB-708. Calithera Biosciences, Inc. was incorporated in 2010 and is headquartered in South San Francisco, California.

Corporate Governance

Calithera Biosciences, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement